Carregant...
Targeted biological therapies for Graves’ disease and thyroid associated ophthalmopathy. Focus on B cell depletion with Rituximab
Based on experience from the treatment of other autoimmune diseases and due to inherent shortcomings of the existing therapy options for Graves’ disease (GD) and thyroid associated ophthalmopathy (TAO), rituximab was recently introduced as a novel therapy option. Here we summarize the rationale for...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2011
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4053536/ https://ncbi.nlm.nih.gov/pubmed/20455896 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2265.2010.03806.x |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|